Prostate Cancer
Stroma-specific gene expression signature identifies prostate cancer subtype with high recurrence risk.
February 28, 2024
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
February 27, 2024
Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING).
February 27, 2024
Variation in communication of side effects in prostate cancer treatment consultations.
February 27, 2024
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes.
February 27, 2024
Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer.
February 27, 2024
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer.
February 26, 2024
A longitudinal mixed-methods study of pathology explanation clinics in patients with newly diagnosed localized prostate cancer.
February 26, 2024
Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5.
February 26, 2024
A Proposal for the Comprehensive Care of Men on Androgen Deprivation Therapy: Recommendations From the Multidisciplinary Prostate Cancer 360 Working Group.
February 23, 2024
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study.
February 23, 2024
Incidence and survival of secondary malignancies after external beam radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database.
February 23, 2024
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.
February 23, 2024